Durable Response to Immune Checkpoint Inhibition in Small Cell Carcinoma of the Bladder: A Case-Based Review of Immunotherapy and CNS Relapse
Background: Small cell carcinoma of the bladder (SCCB) is a rare, aggressive malignancy with no established standard of care for metastatic disease. The prognosis is dismal; median survival ranges from 12 to 20 months, and long-term survival is exceptional. Case Presentation: We present a 67-year-old man diagnosed in 2...